C.F.R. » Title 21 » CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES › SUBCHAPTER D—DRUGS FOR HUMAN USE › PART 314—APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG › Subpart D—FDA Action on Applications and Abbreviated Applications

21 C.F.R. § 314.152

Notice of withdrawal of approval of an application or abbreviated application for a new drug

Read at: eCFRecfr.gov CornellLII GovInfogovinfo.gov CasesGoogle Scholar

If the Food and Drug Administration withdraws approval of an application or abbreviated application for a new drug, FDA will publish a notice in the Federal Register announcing the withdrawal of approval. If the application or abbreviated application was withdrawn for grounds described in § 314.150(a) or § 314.151, the notice will announce the removal of the drug from the list of approved drugs published under section 505(j)(6) of the act and shall satisfy the requirement of § 314.162(b).

[57 FR 17994, Apr. 28, 1992]
Notes of Decisions
Cited in 1 case (1 in the last 5 years), 2024–2024 · leading case: Vanda Pharm. Inc. v. Food & Drug Admin. (D.D.C. 2024).
Sort: Relevance Newest Treatment
Vanda Pharm. Inc. v. Food & Drug Admin. (D.D.C. 2024). “” 21 C.F.R § 314.152; see Opp’n at 16–18. The “incurably premature” doctrine is not rigidly formalist, however.”
Annotations are extracted automatically from the opinions in the Syfert caselaw corpus and ranked by authority, recency, and treatment. Dots show Syfertize treatment of the citing case itself.